格隆汇8月29日丨复星医药(02196.HK)发布公告，2025年8月29日，公司控股子公司复星医药产业与爱科 诺签订《许可协议》，复星医药产业获爱科诺授予（1）AC-201分子、及（2）任何含有AC-201分子为 活性成分的药物于许可区域（即中国境内及港澳地区）及领域（即用于人类疾病的诊断、预防和治疗） 独占的研究、开发、生产、注册及商业化权利。 AC-201是爱科诺自主研发的口服小分子JAK抑制剂，主要拟用于自身免疫性疾病领域。截至本公告日 期（即2025年8月29日，下同），AC-201的首个适应症（中重度斑块型银屑病）已于中国境内完成II期 临床试验。根据截至目前的临床试验数据，AC-201展现出良好的安全性及耐受性，未观察到严重的不 良事件；其用于中重度斑块型银屑病的II期临床试验数据积极，治疗12周后，三个剂量组均达到主要终 点及关键次要终点。根据IQVIA MIDAS最新数据，2024年，JAK抑制剂于全球范围的销售额约为168亿 美元。 爱科诺成立于2017年12月，注册地为江苏省苏州市，法定代表人为Xiaohu Zhang。爱科诺是一家专注于 小分子创新药研发的企业，截至本公告日期，爱科诺在 ...

Core Viewpoint - Yaojie Ankang successfully listed on the Hong Kong Stock Exchange, marking it as the first company from Nanjing to go public this year, bringing the total number of listed companies in the city to 163 [1][3] Company Overview - Yaojie Ankang focuses on the research and development of small molecule innovative drugs, particularly targeting oncology, inflammation, and cardiovascular diseases [1] - The company has established a pipeline of six clinical-stage candidates and one preclinical candidate, most of which have innovative potential [1] Product Development - The core product, Tinengotinib, is a multi-target kinase inhibitor that aims to block faulty cellular signals to exert anti-tumor effects [1] - Tinengotinib is currently undergoing multiple clinical trials in China and the U.S. for various solid tumors, including cholangiocarcinoma, prostate cancer, and breast cancer [1] - The product has received breakthrough therapy designation from the National Medical Products Administration and orphan drug designation from the FDA for cholangiocarcinoma treatment [1] Financial and Market Position - Yaojie Ankang has completed nine rounds of financing, raising over 1.7 billion yuan [2] - The successful listing on the Hong Kong Stock Exchange is seen as a new starting point for the company in the capital market [2] Support and Policy Environment - The Nanjing Jiangbei New Area has established an overseas listing industry investment fund to support companies like Yaojie Ankang in their listing endeavors [2] - The fund has a total scale of 1 billion yuan and aims to invest in companies planning to list overseas [2] Local Market Context - The listing of Yaojie Ankang is part of a broader trend, with Nanjing having 31 companies listed on the Hong Kong Stock Exchange, making it the capital market with the most new listings in recent years [3] - There are currently four companies in the pipeline for listing, seven that have submitted applications for overseas listings, and 34 companies receiving guidance, indicating a robust local market for IPOs [3]